Key result
NT-proBNP and hs-cTnT show suboptimal accuracy for screening subclinical heart failure in general populations.
Why the study?
The study aimed to establish age- and sex-specific cut-offs for NT-proBNP and hs-troponin T in healthy subjects and evaluate them as screening tools for subclinical heart failure in a general population.
Does measurement of NT-proBNP and high-sensitivity troponin T accurately identify subclinical heart failure in a general population?
Cross-Sectional (n=1,936)
Blinded assessors
No
Does measurement of NT-proBNP and high-sensitivity troponin T accurately identify subclinical heart failure in a general population?
NT-proBNP and hs-troponin T demonstrate low sensitivity and are not recommended as standalone screening tools to rule out unrecognized heart failure in the general population.
Answers are grounded in this paper and cite their sources.
NT-proBNP and hs-troponin T should not yet guide subclinical HF screening in general populations; cross-sectional data leave open optimized thresholds in prospective cohorts.
AIMS: The aim of this study was to establish age-specific and sex-specific cut-off values for N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponin T (hs-troponin T) in healthy subjects and assess cardiac biomarkers as screening tools for subclinical heart failure (HF) in a general population. METHODS AND RESULTS: Altogether, 1936 participants were randomly selected from the general population Tromsø 7 study in Northern Norway. Diagnostic accuracy (sensitivity, specificity, and negative and positive predictive value) of cardiac markers for echocardiographically defined subclinical HF was evaluated. The receiver-operating characteristic analysis showed that areas under the curve were relatively low (under 0.75) for both NT-proBNP and hs-troponin T, suggesting that the diagnostic accuracy of these biomarkers for subclinical HF was not excellent, especially for mild forms of HF and younger age group 40-49 years. Sex-specific and age-specific cut-offs for hs-troponin T (99th percentiles) and NT-proBNP (97.5th percentiles) were established in healthy subjects from the same general population. The sex-specific and age-specific cut-offs for NT-proBNP had higher specificity for subclinical HF compared with the previously established single cut-off 125 pg/mL. Age-specific cut-off for hs-troponin T (18 ng/L) for men ≥60 years had also higher specificity than the single cut-off 14 ng/L. These cut-offs had high specificity, but low sensitivity, that makes hs-troponin T and NT-proBNP good biomarkers to rule in HF in case of a positive test, but not good enough to rule out all unrecognized HF due to false negative results. CONCLUSIONS: N-terminal pro-brain natriuretic peptide and hs-troponin T are suboptimal screening tools for subclinical HF in a general population due to low sensitivity.
No takes yet. Share an insight, caveat, or question.
Averina et al. (2022) conducted a cross-sectional in Subclinical Chronic Heart Failure (n=1,936). NT-proBNP and high-sensitivity troponin T testing was evaluated on Diagnostic accuracy (AUC) for echocardiographically defined subclinical heart failure (AUC < 0.75). NT-proBNP and high-sensitivity troponin T testing demonstrated low sensitivity and an area under the curve of <0.75, making them suboptimal screening tools for subclinical heart failure in a general population.
Synapse has enriched 10 related papers. Consider them for comparative context: